Iambic Prices $150 Million Initial Public Offering

Company Iambic Therapeutics Event Type Financing (Initial Public Offering) Modality Small molecule; AI-enabled drug discovery (NeuralPLexer, Enchant) Asset IAM1363 Target HER2 (pan-mutant) Disease Area HER2-altered solid tumors (breast, gastric, lung and others) Summary Iambic Therapeutics priced its initial public offering of 9,375,000 common shares at…